Actively Recruiting
Evaluation of TNX-102 SL Compared to Placebo in Adults With Major Depressive Disorder
Led by Tonix Pharmaceuticals, Inc. · Updated on 2026-10-30
360
Participants Needed
27
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug TNX-102 SL to see if it helps treat adults with moderate to severe major depressive disorder MDD. This study aims to compare TNX-102 SL with a placebo to determine its effect on depression symptoms using a rating scale, and to assess the safety and medical issues participants may experience while taking the drug. Participants will take either 5.6 mg of TNX-102 SL two 2.8 mg tablets or matching placebo tablets every night at bedtime for six weeks. During the study, participants will visit the clinic every two weeks for checkups and tests to monitor their progress. Throughout the study, researchers will assess changes in depression severity using the MADRS score and other measures such as sleep disturbance and clinical impression scales. Safety and tolerability will also be monitored. Participation involves regular clinic visits over the six-week treatment period, with assessments occurring at baseline and every two weeks until the study concludes.
CONDITIONS
Brief Title
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Research Team
T
Timothy Roush
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here